 |
| |
 | | Prevention | |
|
Provide appropriate hydration and administer uric acid-lowering drugs to patients receiving chemotherapy for hematologic cancer who will have substantial tumor lysis.  |
- Start allopurinol therapy (600 mg on day 1 and adjust dose for renal function to 100-300 mg/d) during chemotherapy for hematologic cancer, such as acute leukemias or high-grade lymphomas, unless the patient is known to be allergic to allopurinol.
- Note that some guidelines have recommended rasburicase, 0.1 to 0.2 mg/kg·d for 1 to 7 days, for tumors associated with a high risk of tumor lysis syndrome.
| Background
| | | FAQs |
|
| Grace P. Teal, MD (deceased) has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Howard A. Fuchs, MD, is a consultant for TAP Pharmaceuticals.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott. |
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Gout
